BRINGING THE BENCH
TO THE BEDSIDE.
ProBio ('Prostate Biomarkers') is an international, multi-centre, outcome-adaptive, multi-arm, multiple assignment, randomised controlled, biomarker-driven, phase 3, platform trial in men with de novo metastatic hormone-sensitive (mHSPC) or metastatic castration-resistant (mCRPC) prostate cancer. Patients will be randomised to receive either standard-of-care or one of the experimental treatment arms with a novel hormonal agent (NHA), taxane- or platinum-based chemotherapy, or PARP inhibitor, based on predefined biomarker signatures. The pre-specified biomarker signatures are inferred from plasma cell-free DNA (cfDNA) and/or FFPE diagnostic biopsy DNA profiling using a prostate-specific gene panel.